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Abstract
Objective—Many cell types lose responsiveness to anabolic factors during inflammation and 
disease. Osteogenic Protein 1 (OP1/BMP7) was evaluated for the ability to enhance extracellular 
matrix synthesis in healthy and OA meniscus cells. Mechanisms of cell response to OP1 were 
explored.
Design—Meniscus and cartilage tissues from healthy tissue donors and osteoarthritis patients 
undergoing total knee arthroplasties were acquired. Primary cell cultures were stimulated with 
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OP1 and/or inflammatory factors (IL1α, IL1β, or fibronectin fragments (FnF)) and cellular 
responses were analyzed by RT-qPCR and immunoblots. Frozen section immunohistochemistry 
was conducted to assess OP1 and receptor proteins in normal and OA meniscus.
Results—OP1 treatment of normal meniscus cells resulted in significant, dose-dependent 
increases in ACAN (aggrecan) and COL2A1, and decreased MMP13 gene transcription, while 
only ACAN was upregulated (p<0.01) at the highest dose of OP1 in OA meniscus cells. OP1 
induced significantly more ACAN gene transcription in normal meniscus than normal articular 
cartilage (p=0.05), and no differences between normal and OA cartilage were detected. Receptor 
expression and kinetics of canonical signaling activation were similar between normal and OA 
specimens. Normal meniscus cells treated with inflammatory factors were refractory to OP1 
stimulation. Smad1 phosphorylation at an inhibitory site was induced (p=0.01 for both normal and 
OA meniscus) by inflammatory cytokine treatment.
Conclusions—The meniscus demonstrates resistance to OP1 stimulation in OA and in the 
presence of inflammatory mediators. MAPK-mediated Smad1 linker phosphorylation is a possible 
mediator of the loss of anabolic extracellular matrix production in the inflammatory cytokine 
affected meniscus.
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Introduction
The meniscus is a crescent-shaped fibrocartilaginous tissue that provides important 
biomechanical and biological functions in the knee such as supporting joint stability, 
reducing joint contact stress upon the articular cartilage, and contributing biologically to 
joint nutrition, lubrication, and proprioception [1]. The meniscus is frequently injured and 
not easily repaired, particularly in the inner region which lacks vascularization and retains 
more cartilage-like properties [2]. Approximately 35% of the general population between 
19–50 years of age has meniscus tears identified by MRI, with incidence increasing with age 
[3], and up to 91% in symptomatic osteoarthritis (OA) patients [4]. Following meniscus 
injury, OA is often induced where changes to the articular cartilage structure become 
apparent within several years [5]. Approximately 50% of patients with tears treated by 
meniscectomy have radiographic OA within 16 years [6]. This suggests that the meniscus is 
an important target in studies of OA.
OA is a process of lost tissue homeostasis and abnormal remodeling, in which catabolic 
breakdown exceeds matrix synthesis in a process driven by inflammatory mediators within 
the affected joint [7, 8]. Consistent with other OA affected tissues, injured menisci produce 
inflammatory factors and matrix metalloproteases which enhance meniscus degeneration 
and OA progression [9–12]. Although it has not been studied in the meniscus, it is likely that 
inflammatory cytokines released from the injured meniscus also inhibit anabolic factors 
associated with matrix synthesis. Retention of meniscus extracellular matrix following 
meniscus injury and catabolic factor release is likely to slow or prevent OA progression [9–
12].
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Osteogenic Protein 1 (OP1/BMP7), a Bone Morphogenetic Protein (BMP) and 
Transforming Growth Factor β (TGFβ) family member, is a candidate for stimulating 
meniscus matrix synthesis. OP1 stimulates matrix synthesis in cells of related tissues such as 
articular cartilage, ligament, and bone. Treatment of articular cartilage with OP1 both in 
vitro and in vivo is chondroprotective and enhances anabolic matrix synthesis and 
proteoglycan production without inducing abnormal anabolism, such as osteophyte 
formation [13]. OP1 is also anti-catabolic in articular cartilage, as treatment prevents matrix 
metalloprotease stimulation by modulating the effect of inflammatory and catabolic 
mediators such as Interleukin 1β (IL1β) and fragments of the matrix protein fibronectin 
(FnF) [13]. Research has shown that the animal meniscus responds to OP1 with enhanced 
proteoglycan and collagen production [14–16]. However, no studies have investigated OP1 
effects on the human meniscus using tissue from normal and OA joints. Information about 
the responsiveness to OP1 is needed if it is to be considered as a potential therapeutic 
intervention.
OP1 signaling occurs via a common signaling pathway characteristic of BMP family 
members. Following binding to a receptor complex, specific type I receptors (ALK-2, -3, or 
-6) transduce the signal by phosphorylating the C-terminus SVS motif at Ser463/Ser465 of 
intracellular targets Smads 1, 5, and 8 [17, 18]. A conformation change of Smad1/5/8 opens 
a binding site for the Smad4 cofactor. The Smad1/5/8 and Smad4 complex then translocate 
to the nucleus to interact with transcription factors on promoter elements of target genes. 
[19].
The objective of this study was to evaluate the ability of OP1 to stimulate meniscus matrix 
synthesis in cells derived from normal and OA meniscus tissue. Identification of a decreased 
response to OP1 in cells from OA joints led us to explore potential mechanisms for 
resistance to OP1 in OA meniscus cells.
Methods
Cell Culture
Normal human menisci and femoral articular cartilage (28–82 years, mean= 67) were 
obtained from organ donors through the Gift of Hope Organ and Tissue Donor Network 
(Itasca, IL), or from the National Disease Research Interchange (NDRI, Philadelphia, PA). 
Normal tissue had a score of 0–2 within the International Cartilage Research Society 
Cartilage Morphology Score (ICRS) or a meniscus modified ICRS which ranged from 0–4 
[9]. OA meniscus and/or cartilage (54–74 years, mean=65) were obtained as discarded tissue 
from total knee arthroplasties performed at Wake Forest Baptist Medical Center (Winston-
Salem, NC). Human donor tissue research was approved by the IRBs at Rush University and 
Wake Forest University School of Medicine. All comparisons between meniscus and 
articular cartilage were from the same knee and therefore were donor-matched samples 
(n=14 total matched donors). In experiments using inner vs outer meniscus regions, the inner 
1/3 of the meniscus was excised and processed separately from the outer region. Tissue was 
digested and cells were harvested as described previously [9]. Primary meniscus cells and 
articular chondrocytes were grown as high density monolayer cultures with 10% serum in 
DMEM media (Gibco) until confluent, changed to mini-ITS or serum free media upon 
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reaching confluence. Cells were treated with OP1 (25–500 ng/mL for initial dose response 
and 100 ng/mL used for all subsequent experiments, Stryker Biotech). In signaling 
experiments, OP-1 stimulation was compared to IL1α, IL1β (10 ng/mL, R&D Systems), 
TGFβ1, IGF1 (100 ng/mL, R&D Systems), GDF5 (100 ng/mL, Prospec), or FnF (1 μM), a 
recombinant fragment of fibronectin protein containing domains 7–10 of full length 
fibronectin [20] for 24 hours or as indicated. These factors were chosen for comparison to 
OP1 because IL1α, IL1β, and FnF are known to stimulate MAPK signaling, TGFβ 
stimulates Smad2 signaling, IGF1 stimulates AKT activation, and GDF5 stimulates 
Smad1/5/8 signaling. All treatment doses were selected to be within biologically relevant 
ranges of those found in synovial fluid or joint tissue except IL1α and IL1β, for which doses 
used were selected based on previous studies examining their role in mediating catabolic 
signaling [13, 21].
Quantitative Real-time PCR
Total RNA was extracted using TRIzol (Invitrogen) and concentrations were determined by 
a nanodrop 1000 spectrophotometer (Thermo Scientific). Total RNA was used to synthesize 
cDNA (Retroscript RT kit) and RT-qPCR amplification was performed on a 7900HT Fast 
Real-Time PCR System with Taqman Mastermix and manufacturer recommended primer-
probe sets (Applied Biosystems). All data were normalized to the endogenous control gene 
TATA box-binding protein (TBP) measured in parallel samples and calculated using the 2-
ΔΔct method. In preliminary studies we have found TBP to be more reliable than GAPDH or 
other “housekeeping” genes as a constitutively expressed control in meniscus cells. Graphs 
showing Normalized Expression reflect this calculation. Graphs showing Relative 
Expression present results normalized to TBP and then expressed as fold differences relative 
to unstimulated control cells (set to 0) for each donor in each experiment. Unstimulated 
normal cells from each donor sample served as the control for OP-1 stimulated normal cells 
from the same donor and unstimulated OA cells from each OA patient served as the control 
for the OP-1 stimulated OA cells from the same patient. Endogenous OP1 and BMP receptor 
expression levels were determined using RT-qPCR arrays for which RNA was purified using 
the RNEasy Mini kit (Qiagen) and used for the RT2 Profiler™ PCR Array Human TGFβ / 
BMP Signaling Pathway (SABiosciences) for the Applied Biosystems 7900HT thermocycler 
according to the manufacturer’s protocol. For these experiments, the geometric average from 
a panel of endogenous control genes including B2M HPRPT1, RPL13A, GAPDH, ACTB 
was used to normalize raw cts of OP1 and BMP receptors using the 2-ΔΔct method and 
graphed as normalized data.
Immunoblot Analysis
Cell signaling studies were performed as previously described [9], with cultures lysed at the 
indicated time points and lysates used to analyze cell signaling proteins by immunoblot. 
Cell-conditioned media was collected 24 hours post stimulation for MMP analyses. 
Phospho-Smad1/5/8 (Ser463/Ser465)/(Ser426/Ser428), phospho-Smad1linker region 
(Ser206), total-Smad1, phospho-Smad2 (Ser465/Ser467), total-Smad 2, phospho-p38 
(Thr180/Tyr182), total-p38, phospho–ERK-1/2 (Thr202/Tyr204), total-ERK-1/2, phospho-
Akt (Ser473), total-Akt, and secondary anti-mouse and anti-rabbit antibodies were all 
obtained from Cell Signaling Technology. The phospho-JNK (Tyr183/Tyr185) and JNK-2 
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antibodies were obtained from Invitrogen. The β-actin, MMP2, and MMP13 antibodies were 
from Abcam. MMP1 (Abnova) and MMP3 (Millipore) antibodies were also used. 
Densitometry was performed using ImageJ 1.48v analysis software. MMP-1,-3, and -13 
were normalized to MMP2 since its levels in conditioned media were not changed by the 
treatments tested. Phospho-Smad1linker region was normalized to total-Smad1. Phospho-
Smad2 was normalized to total-Smad2. Because the phospho-Smad1/5/8 antibody 
recognizes a phosphorylation site in all 3 of the Smads and therefore cannot distinguish 
Smad1 from Smad5 or Smad8, β-actin was used to normalize phospho-Smad1/5/8 
densitometry.
Immunohistochemistry
Human meniscus tissue excised from the body of the lateral meniscus (n=3 normal and n=3 
OA) was snap frozen in OCT (Fisher Scientific) and sectioned at 5 μm. Immunostaining was 
automated (Leica Bond-max™, Leica Microsystems Inc., Bannockburn, IL) following 
manual optimization (Vector labs) protocols. Sections were washed with PBS between each 
of the following steps: fixed for 10 minutes in acetone, treated with Bloxall, Dako Serum 
Free Protein Block, followed by primary antibody diluted in Dake antibody Diluent. 
Antibodies consisted of anti-mature OP1 (Stryker Biotech), ALK2 (LSBio), ALK3 (Gene 
Tex), ALK6 (Bioorybt), and secondary anti-rabbit (Vector labs). RTU Elite was then added. 
The DAB chromagen was added and neutralized within 2 minutes. Slides were 
counterstained with Gill’s hematoxylin and mounted with MM24. Slides were scanned with 
an Olympus VS110, version 2.7, with VS-ASW FL software. The objectives are true 
Olympus 40X and images shown at 10x. OlyVIA is the viewing software for the VSI image 
format.
Statistical Analysis
Results are shown as dot plots which reflect individual data points, and the mean ± CI from 
at least 3 independent donors. Data were analyzed with SAS version 9.4 (SAS Institute, Inc. 
Cary, NC). Experimental control-normalized data were log or square root transformed to 
correct for skewness if necessary. In order to account for within-donor correlations, all 
regression analyses were conducted using mixed modelling techniques: dose response 
experiments used a repeated measures framework; experiments of donor-matched tissues 
used linear mixed models; and longitudinal regression models were used to evaluate time 
courses. T-tests were used to compare inflammatory cytokine stimulation to inflammatory 
cytokine with OP1 co-treatment. Post hoc tests were conducted with Dunnett’s adjustment 
for multiple comparisons to evaluate differences from the control treatment within normal 
and OA groups or Tukey-Kramer adjustment for multiple comparisons to further define 
differences between normal and OA groups.
Results
Comparison of Normal and OA Meniscus Cell Response to OP1
We stimulated normal and OA meniscus cells with increasing doses of OP1 and analyzed the 
effects on extracellular matrix and matrix metalloprotease (MMP) gene transcription. 
Following OP1 treatment in normal cells, we observed dose-dependent increases in 
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transcript levels of ACAN (aggrecan) which were significantly greater than the untreated 
controls starting at the 100ng/ml dose. However, compared to normal cells, ACAN 
expression was upregulated to a lesser degree in OA meniscus cells following OP1 
treatment, with significant difference between untreated OA control cells only detected at 
the highest (500ng/ml) dose of OP1 (Figure 1). OP-1 significantly increased COL2A1 
(collagen type II) mRNA levels in cells isolated from normal meniscus at the 100, 300, and 
500 ng/mL dose as compared to untreated control cells (0 ng/mL) from normal meniscus. 
No differences were detected in OA meniscus cells treated with OP1 when compared to the 
untreated OA control cells. Gene expression of MMP13 was significantly downregulated 
during OP1 stimulation in normal cells at each OP-1 dose compared to unstimulated normal 
cells, but not in OA cells compared to unstimulated OA cells. A modest increase in MMP1 
occurred in normal cells at the 100 ng/ mL dose of OP1 (fold change of 0.302, p=0.0278) 
and in OA cells at the 300 ng/mL dose (fold change of 0.811, p=0.0321), but significance 
was not found at other doses (data not shown). Transcript levels of COL1A1, COL3A1, and 
MMP3 were not significantly changed in normal or OA cells in response to OP1 at any dose 
(data not shown). From this experiment, we chose to stimulate cells in all subsequent 
experiments with OP1 at 100 ng/mL, a biologically relevant dose [21, 22].
The OP1 response in cells from donor-matched meniscus and articular cartilage from both 
normal and OA knee joints were compared. Data for each gene were normalized to TBP and 
then presented as the expression relative to unstimulated cells for each experiment (i.e. OP1 
stimulated normal meniscus cells relative to unstimulated normal meniscus cells). OP1 
stimulated significantly greater ACAN expression in normal meniscus cells than either OA 
meniscus cells or articular chondrocytes from either normal or OA joints (Figure 2A). 
COL2A1 was also increased by OP1 in normal meniscus to a significantly greater extent 
than in cells from OA meniscus. Differences in MMP13 expression in meniscus and 
cartilage were not detected. No differences in gene expression were identified between 
normal and OA chondrocytes. The inner region of the meniscus is often lost to degeneration 
during OA [2]. We analyzed the response of cells from healthy meniscus tissue by region to 
determine if the loss of inner region tissue was responsible for reduced response to OP1 in 
OA meniscus. The mRNA levels of ACAN and COL2A1 upon OP1 stimulation were 
comparable between the healthy meniscus regions, and no significant differences were 
detected (Figure 2B). MMP13 was more significantly down-regulated in the inner meniscus 
cells compared to other regions and articular chondrocytes.
Endogenous Expression of OP1 and BMP Receptors in Meniscus
We evaluated endogenous levels of OP1 and type I BMP receptors in normal and OA 
meniscus cells by mRNA and immunohistochemistry (IHC). No significant differences were 
found between normal and OA meniscus mRNA levels of BMP7 (OP1) and the type I BMP 
receptors ACVR1 (Activin receptor-like kinase-2 or ALK2), BMPR1A (ALK3), and 
BMPR1B (ALK6)(Figure 3 A, B). IHC staining showed an increased amount of OP1 in 
normal tissue over OA tissue (Figure 3C). BMP type I receptor protein staining was apparent 
in both normal and OA menisci.
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Normal and OA meniscus cell response to OP1 during inflammatory factor treatment
OP1 has been shown to reduce MMP production by modulating the effect of inflammatory 
and catabolic mediators in articular cartilage [13]. Normal and OA meniscus cells, with or 
without OP1, were treated with FnF, IL1α, or IL1β. Immunoblots of conditioned media were 
probed for MMP-1, -3, or -13 and normalized to MMP2, for which levels remained stable. 
Densitometry of immunoblots revealed that normal cells secreted significantly more MMP1 
and MMP3 when stimulated with inflammatory cytokines (Figure 4 A, B, C). MMP13 was 
not detected by immunoblot of normal cells. Likewise, OA cells secreted significantly more 
MMP1 and MMP13 when stimulated with inflammatory cytokines (Figure 4 D, E, F, G). 
Across both normal and OA meniscus, OP1 (100 ng/mL) addition did not alleviate MMP 
secretion basally or with inflammatory factor addition. We also tested the ability of OP1 to 
modulate gene transcription in parallel experiments. OP1 co-stimulation with any of the 
inflammatory factors was not able to influence gene expression for either normal or OA 
donors (Figure 5). In general, IL1α, IL1β, and FnF increased MMP -1, -3, and -13 gene 
expression and decreased anabolic matrix gene transcription, but OP1 was not able to restore 
gene expression in the presence of any of the tested inflammatory factors.
OP1 Effects on Normal and OA Meniscus Cell Signaling
Phosphorylation of the c-terminus of the Smad1/5/8 transcription factors (p-Smad1/5/8) is 
the result of canonical BMP signaling activation. Whether or not OP1 activates non-
canonical pathways such as MAPKs or AKT in the meniscus has not been reported. Thus, 
we examined the kinetics of OP1-induced phosphorylation of these proteins in normal and 
OA meniscus. We found that OP1 only activated canonical, Smad1/5/8 phosphorylation (P-
Smad1/5/8) in both normal and OA meniscus and not non-canonical signaling, as compared 
to TGFβ, IL1β, GDF5, or IGF1 (Figure 6A normal donor, Figure 6B OA donor). Smad1/5/8 
phosphorylation significantly increased over time in response to OP1 treatment in normal 
and OA donors (p<0.001), beginning at 30 minutes and peaking at 1.5 hours, but no 
differences in kinetics were found between normal and OA donors (Figure 6C). As expected, 
IL1β and IGF1 failed to induce significant, canonical Smad1/5/8 phosphorylation. IL1β was 
the only stimulus which induced phosphorylation of the MAPKs (p38, ERK, JNK), while 
IGF1 was the only stimulus which induced AKT phosphorylation in both normal and OA 
meniscus cells. GDF5 was a less potent stimulator of canonical Smad1/5/8 phosphorylation 
than OP1. TGFβ induced both Smad1/5/8 phosphorylation and Smad2 phosphorylation in 
normal and OA meniscus.
Smad1 Linker Region Phosphorylation in meniscal cells
The ability of Smad1 to regulate transcription can be inhibited by phosphorylation of the 
interdomain linker region by inflammatory factor-activated MAPK [16, 23–25]. We 
compared the intensity of canonical (P-Smad1/5/8) and non-canonical linker region (P-
Smad1, S206) Smad1 phosphorylation between normal and OA meniscus cells, and also 
evaluated TGFβ-associated Smad2 C-terminus phosphorylation (P-Smad2). In normal cells, 
significant increases in P-Smad1/5/8 were detected in response to OP1 at 90 minutes and to 
TGFβ at 30 minutes. OA meniscus cells had a trend of higher basal P-Smad1/5/8 than 
normal cells although no significant differences were detected (Figure 7B). Phosphorylation 
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at Serine 206 in the Smad1 linker region was significantly increased in response to IL1β in 
both normal and OA samples versus unstimulated controls (Figure 7C). TGFβ significantly 
increased phosphorylated Smad2 above control levels in both normal and OA meniscus cells 
(Figure 7D). As expected, IL1β did not alter P-Smad1/5/8 or P-Smad2. No differences were 
detected between intensity of phosphorylation of the evaluated proteins between normal and 
OA tissues.
Discussion
These results identify OP1 as an anabolic agent in normal human meniscus cells which does 
not promote catabolic processes. Importantly, the reduced ability of OP1 to stimulate 
extracellular matrix gene expression and to reduce MMP expression in meniscus cells 
obtained from end-stage OA knee joints suggests that factors associated with OA inhibit the 
response to OP1. We found evidence that these could include IL1α, IL1β, and FnF which 
have been found to be present in torn meniscus and/or OA joint fluid [26, 27]. We also 
confirmed previous work [13] that unlike the meniscus, OA chondrocytes do not appear to 
become unresponsive to OP1 suggesting differences in the regulation of OP1 signaling 
between these two joint tissues.
Previous work has shown that OP1 stimulates proteoglycan and collagen production in pig, 
rat, and sheep meniscus [14–16]. We further explored this using human tissue and found that 
ACAN and COL2A1 were upregulated in normal meniscus cells and MMP13 was 
downregulated. Our study also evaluated the effect of OP1 on meniscus cells derived from 
human OA joints, in which the stimulatory effects of OP1 on extracellular matrix gene 
expression was lost in all evaluations except for ACAN induction using a high dose (500 
ng/mL) of OP1. However, OP1 did not induce COL1A1, COL3A1, or MMPs in normal or 
OA meniscus cells, which supports that OP1 induces neither fibrotic nor catabolic processes 
in the meniscus. Lack of induction of these genes is also consistent with published reports in 
articular cartilage [13, 28].
Unlike meniscus, OP1 has been extensively studied in articular cartilage. Surprisingly, we 
found that the normal meniscus expressed higher levels of ACAN in response to OP1 than 
matched articular cartilage from the same donor, while OA meniscal cells but not OA 
chondrocytes lost responsiveness to OP1. ACAN and COL2A1 are OP1 responsive genes in 
articular cartilage [28, 29] and this held true in the meniscus. We did not find a differential 
response to OP1 stimulated ACAN or COL2A1 expression by separated meniscus regions, 
ruling out the possibility that the inner region, which is higher in aggrecan and collagen type 
II expression and often lost to degeneration during OA [2, 30], was responsible for OP1 
response. This suggests that anabolic insensitivity of meniscus cells to OP1 in OA is related 
to disease state and not due to loss of the inner meniscus region in OA.
We unexpectedly identified that normal articular chondrocytes were less responsive to OP1 
than normal meniscal cells as measured by ACAN levels. Our comparative experiments used 
meniscus cells and chondrocytes from the same donor knees. Thus the pre-existing knee 
joint environment was shared, and cells were processed and treated in parallel, nearly 
eliminating the possibility of differential cell stress or treatment. It is also unlikely that 
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articular chondrocytes have high endogenous levels of the Smad1 linker region 
phosphorylation. Several papers, from which we based our cell isolation, cell treatment, and 
immunoblot techniques, showed that IL1β or tert-butyl hydroperoxide to induce oxidative 
stress were required to detect phosphorylation in the linker region of Smad1 [21, 31]. 
Articular cartilage expresses 5 times as many proteoglycans as the meniscus on a protein 
level [32]. Our data of endogenous expression suggests that articular chondrocytes express 
approximately 40 times more ACAN than the meniscus cells on a gene level. This suggests 
that OP1 could have less effect on articular chondrocytes due to the already elevated 
expression of ACAN and due to complex regulation of this gene in articular cartilage [33]. 
As a more fibro-cartilagenous tissue, the healthy meniscus may have more ability to respond 
to OP1 and gain a more cartilage-like ECM composition.
Type I BMP receptors assist in signal transduction across the cell membrane and confer 
specificity of intracellular BMP signals [34, 35]. We evaluated expression of endogenous 
OP1 and the BMP type I receptors (ALK -2, -3, and -6) in normal and OA tissues to assess if 
OA impacts receptors available for signal transduction. OP1 and BMP receptor protein 
staining was apparent in both normal and OA meniscus. We did not identify differences in 
mRNA levels of OP1 or receptors between normal and OA meniscus. OP1 has been shown 
to bind strongly to ALK2 or weakly to ALK6 [36]. Because we observed similar expression 
of these receptors in normal and OA meniscus, we chose to look further downstream in the 
BMP signaling pathway for a possible explanation for anabolic resistance to OP1 in OA 
meniscal cells.
The signaling events incited by inflammatory factors released from injured and OA menisci, 
including IL1α, IL1β, and FnF [26, 27] culminate in meniscus tissue breakdown and OA 
progression [9–12]. It has been less studied, but inflammatory factors also inhibit intrinsic 
meniscal repair [37], and likely set up the joint for subsequent damage. Our objective in the 
present study was to model the inflammation which occurs following meniscus injury and 
OA. Hence we used a high-dose (10 ng/mL) of IL1α and IL1β to induce inflammation, as 
has been previously published [13, 21]. Using this model in articular chondrocytes, OP1 was 
not able to compensate for IL1β induced downregulation in aggrecan expression [21], 
consistent with our findings. However, OP1 was able to decrease MMP1 and MMP13 
promoter activity in human chondrocytes following 25 ng/mL IL1β [38], while we saw no 
OP1-induced change in MMP gene and protein expression in our experiments. Hence our 
choice of 10 ng/mL was likely the most informative dose for this first study of OP1 effects in 
the meniscus during inflammation and OA. We also used an OA-physiological dose of 
fibronectin fragment (FnF) (1 μM) [27]. In articular chondrocytes, OP1 was able to block, as 
well as restore, PG loss induced by FnF [39], while we failed to identify any restoration of 
anabolic gene transcription or reduction of MMP gene and protein expression. Our study 
indicates inhibition of OP1 occurs during inflammation and also at a physiological 
concentration FnF in the meniscus. In other studies, the meniscus has been found to be more 
sensitive to catabolic factors than articular cartilage [40]. Inflammatory factors also inhibit 
intrinsic meniscal repair [37], and likely set up the joint for subsequent damage. Although 
there is variation in methodology, this further suggests differences in meniscus and cartilage 
metabolism, and a potentially greater sensitivity of the meniscus to inflammation-inhibited 
repair processes.
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BMP signal transduction from the cell surface to the nucleus occurs via the Smad 
transcription factors, which are central mediators of this pathway [41]. Ligand-activated 
BMP receptors phosphorylate the Smad1/5/8 transcription factors at the canonical, activating 
c-terminus. This results in co-factor recruitment, nuclear accumulation, association with 
other transcription cofactors, and gene transcription [42]. Alternatively, non-canonical BMP 
signaling can activate the MAPKs, and AKT pathways [42, 43]. We identified similar 
kinetics of canonical, activated Smad1/5/8 (p-Smad1/5/8) between normal and OA donors. 
OP1 did not activate non-canonical pathways in the meniscus, including the p38, ERK, and 
JNK MAPKs, Smad2, or AKT.
Convergence of inflammatory cytokine activated MAPK and BMP signaling results in BMP 
signaling constraint at the level of Smad1. This occurs via non-canonical, inhibitory 
phosphorylation of Smad1 at the interdomain linker region by MAPKs. Smad1 linker region 
phosphorylation at serines of PXSP motifs by MAPKs has been shown to limit nuclear 
accumulation, reduce transcription activity, and induce Smad1 degradation in developmental 
models [16, 23–25]. This potential mechanism for OP1 resistance had not been studied in 
the meniscus, but many of the inflammatory cytokines associated with the torn or 
degenerative menisci, including IL1 and FnF, activate the MAPKs [44], and phosphorylated 
p38 MAPK has been identified histologically from torn menisci [45]. In articular cartilage, 
IL1β has been shown to increase Smad1 linker region phosphorylation through p38 MAPK 
[21, 31]. In our study, Smad1 linker region phosphorylation, as indicated by the antibody to 
detect phosphorylation at serine 206, was enhanced during IL1β stimulation in normal and 
OA meniscus cells. In conjunction with our experiments showing that cells treated with 
inflammatory cytokines were also refractory to OP1 stimulation, this suggests that Smad1 
linker region phosphorylation may be a mechanism contributing to OP1 insensitivity 
following inflammatory events.
TGFβ signaling in articular chondrocytes has been shown to be altered during aging and OA, 
with a switch in prominence from Smad2/3 to the BMP-related Smad1/5/8 resulting in 
MMP13 expression and loss of tissue homeostasis [46]. In articular cartilage, TGFβ 
stimulated phosphorylation of Smad1/5/8 is thought to recapitulate chondrocyte terminal 
differentiation and induces cartilage degeneration, synovial fibrosis, and osteophyte 
formation [47]. In contrast to chondrocytes, TGFβ induced significant increases in 
phosphorylation of Smad1/5/8 in cells isolated from both normal and OA menisci, as well as 
significant increases in phosphorylation of Smad2 in both normal and OA meniscal cells. We 
noted comparable levels of TGFβ stimulated phosphorylation of Smad1/5/8 and Smad2 
when comparing normal and OA human menisci. These findings further exemplify 
differences in chondrocytes and meniscal cells and raise the question of whether the 
meniscus is protected from altered TGFβ signaling during OA. Further study of the 
meniscus in comparison to articular cartilage may indicate signaling differences which can 
be targeted to assist knee joint homeostasis.
Despite the strengths of using a human model of disease, our study carries limitations 
specific to human tissue and cell-culture research. The use of human subjects and associated 
variability may have resulted in failure to statistically identify differences in Smad 
phosphorylation between normal and OA tissues. We attempted transfection experiments in 
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normal human meniscus cells using Smad1 [48] and Smad1 linker region mutants [19] to 
determine if the inhibitory site phosphorylation at serines of PXSP motifs in the Smad1 
linker region was responsible for the reduced response to OP1, but did not observe 
consistent effects. The inability to accomplish these experiments reliably may exemplify the 
importance of Smad1 to normal meniscus cell phenotype and stress regulation, but they also 
highlight the limitations of cell culture studies using primary cells. The meniscus contains a 
mixed cell population reflective of vascularization and different embryonic origins of inner 
and outer meniscal cell regions [2]. No cell lines are available which are representative of 
meniscal cells. Further evaluation of the functional consequence of OP1 signaling and 
Smad1 linker region phosphorylation in the OA meniscus pertinent to anabolic insensitivity 
may require in vivo approaches. These were beyond the scope of the current study.
In summary, these findings support the presence of significant anabolic resistance to OP1 in 
OA menisci. In our experimental model, treatment with inflammatory mediators promotes 
the inhibition to OP1 and also results in Smad1 interdomain linker phosphorylation at a site 
known to inhibit Smad1 transcriptional activity [16, 23–25]. This is the most likely 
explanation for OP1 insensitivity in OA meniscus and cytokine treated normal meniscus. 
Our data also exemplify key differences between meniscus and articular chondrocyte 
responses to OP1 as well as TGFβ. Normal meniscus cells were more responsive to OP1 
than normal chondrocytes but inflammatory mediators induced OP1 insensitivity in normal 
meniscal cells, similar to OA meniscus cells. Unlike reports in chondrocytes [46, 47], there 
was no change in prominence of Smad1/5/8 and Smad2 activation following TGFβ 
stimulation in normal and OA meniscus. The BMP pathway in general is known to have 
variant outcomes following a common intracellular signaling system due to species and cell 
type differences [49]. Our work, conducted in human adult primary meniscus cells 
exemplifies cell type specific differences. This is of particular interest during injury and OA, 
and highlights the importance of considering tissue specific and whole joint effects of 
potential therapeutics.
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Figure 1. OP1 dose effect on gene expression in normal and OA meniscus cells
Meniscal cells from normal (n=7 independent donors) and OA (n=5 independent donors) 
tissues were treated with 0–500 ng/mL of OP1 for 24 hours. All p values are compared to 
unstimulated controls from the same donor (the 0 ng/mL OP1 dose for the respective normal 
or OA cells) unless otherwise indicated by brackets to point out the direct comparisons. P 
values reported on graph or +p=0.03, *p<0.01, **p<0.001 by mixed model with repeated 
measures and post hoc Dunnett’s adjustments or Turkey Kramer adjustments. ACAN= 
aggrecan, COL2A1= collagen type II, MMP13= matrix metalloprotease 13
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Figure 2. Effect of OP1 stimulation on meniscus cells versus articular chondrocytes
A) OP1 (100 ng/mL) 24 hour stimulation of matrix gene expression in meniscal cells and 
chondrocytes from normal, matched donors, and corresponding effect in tissue-matched OA 
donors (n=5 each). B) OP1 (100 ng/mL) for 24 hours effect on normal meniscus cells by 
region vs. cells from whole meniscus and chondrocytes (n=4 matched tissue donors). Data 
for each gene were normalized to the endogenous control gene, TBP, and presented as the 
expression relative to the expression of unstimulated normal or OA cells, respectively. 
Significantly different groups indicated by brackets to point out the direct comparisons. P 
values reported on graph by linear mixed models and post hoc Turkey Kramer adjustments. 
M= meniscus, C= cartilage, IM= inner meniscus, OM= outer meniscus
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Figure 3. Endogenous levels of OP1 and receptors in meniscus
A) BMP7 (OP1) RNA expression from cultured cells of n=3 independent normal and OA 
donors. B) BMP Type I receptor RNA levels ACVR1 (ALK2), BMPR1A (ALK3), and 
BMPR1B (ALK6) in cultured cells from n=3 independent normal and OA donors. C) OP1 
and type I receptor protein localization in meniscus tissue by frozen section 
immunohistochemistry. Data from A and B were normalized to the geometric average from 
a panel of endogenous control genes. IHC images representative of n=3 independent donors. 
Scale bar 100 μM. ALK= Activin receptor-like kinase, No 1°= no primary antibody control
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Figure 4. MMP release from meniscus cells following inflammatory factor treatment and OP1 
co-treatment
Meniscus cells treated for 24 hours with fibronectin fragments (FnF, 1uM), inflammatory 
cytokines (10ng/mL), or OP1 (100 ng/mL). A) Immunoblot of normal human meniscus cells 
and B, C) densitometry of MMP1 and MMP3 from 3 normal human menisci. D) 
Immunoblot of OA human meniscus cells and E, F, G) densitometry of MMP1, MMP3, and 
MMP13 from 3 OA human menisci. MMP-1,-3, and -13 were normalized to MMP2 since its 
levels in conditioned media were not changed by cell treatment. P values by linear mixed 
models and post hoc Dunnett’s adjustments reported on graphs vs. unstimulated controls for 
densitometry from n=3 independent normal and OA donors, each.
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Figure 5. Gene expression of matrix proteins and MMPs in meniscus cells following 
inflammatory factor treatment and OP1 cotreatment
Meniscus cells treated for 24 hours with fibronectin fragments (FnF, 1uM), inflammatory 
cytokines (10ng/mL), or OP1 (100 ng/mL). Data for each gene were normalized to the 
endogenous control gene, TBP. P values are reported on graphs or are *p<0.01, **p<0.001 
vs. unstimulated controls by linear mixed models and post hoc Dunnett’s adjustments. No 
differences were detected between n=3 independent normal and n=3 OA meniscus donors.
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Figure 6. Effect of OP1 on kinetics of canonical Smad1/5/8 signaling and non-canonical signaling
OP1 (100 ng/mL) treatment over time in both (A) normal meniscus cells and (B) OA 
meniscus cells as compared to positive controls for each signaling pathway. Positive controls 
consisted of TGFβ activation of Smad2, IL1β activation of MAPKs (p38, ERK, JNK), and 
IGF1 activation of AKT. GDF5 was also evaluated for activation of Smad1/5/8. (C) 
Densitometry of P-Smad 1/5/8 from n=4 independent normal donors and n=4 independent 
OA donors reveals a difference over time (p<0.001 by longitudinal mixed models) in 
response to OP1 stimulation, but no difference between disease state. P-Smad 1/5/8= 
canonical Smad1/5/8 phosphorylation. Non-canonical pathways evaluated include P-
Smad2=phosphorylated Smad2, P-p38= phosphorylated p38, P-ERK= phosphorylated 
extracellular signal-regulated kinases, P-JNK= phosphorylated c-Jun N-terminal kinases, 
and P-AKT= phosphorylated AKT/protein kinase B
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Figure 7. Direct comparison of normal and OA meniscus cell activation of canonical and non-
canonical Smad phosphorylation
OP1 (100 ng/mL), ILIβ (10 ng/mL), or TGFβ (100 ng/mL) stimulation at select time points. 
A) Immunoblot representative of n=3 independent experiments. B) Densitometry of 
canonical Smad 1/5/8 phosphorylation (p-Smad1/5/8) from n=3 independent normal and OA 
donors. C) Densitometry of non-canonical linker region Smad1 (p-Smad1 (S206)), an 
inhibitory phosphorylation for Smad1 transcription factor activity, from n=3 independent 
normal and OA donors. D) Densitometry of phosphorylated Smad 2 (p-Smad2) from n=3 
independent normal and OA donors. Phospho-Smad1linker region was normalized to Total-
Smad1. Phospho-Smad2 was normalized to Total-Smad2. Because the phospho-Smad1/5/8 
antibody recognizes a phosphorylation site in all 3 of the Smads and therefore cannot 
distinguish Smad1 from Smad5 or Smad8, β-actin was used to normalize phospho-
Smad1/5/8 densitometry. P values by linear mixed models and post hoc Dunnett’s 
adjustments reported on graphs vs. unstimulated controls for densitometry from n=3 normal 
and OA donors, each.
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